Abstract:Abstract Background: The cGAS-STING signaling pathway has led to significant anti-cancer innate immune responses in cancer immunotherapy. 2’3’-cGAMP binds to STING and promotes the production of various pro-inflammatory cytokines such as type I interferon, which changes cold tumors to hot tumors through modulating tumor microenvironment. Therefore, activation of STING pathway has been considered as an important target for cancer immunotherapy. Ecto-Nucleotide Pyrophosphatase/Phosphodiesterases 1 (ENPP1), highly expressed membrane-bound enzyme in cancer cells, modulates cGAMP levels by hydrolyzing 2’,3’-cGAMP to alter the inflammatory mileu. In this study, we show that targeting ENPP1 is a promising strategy for STING regulation in cancer immunotherapy through indirect activation of the STING pathway. Methods: The ENPP1 inhibitory activities were measured by ENPP1 enzyme assay using both pNP-TMP and cGAMP as substrates. Cell-based activities were assessed by measuring IFN-beta release using THP-1 dual reporter assay. To validate biological functions, we evaluated cancer-cell killing effects of immune cells in co-culture spheroid system and T cell proliferation assay. The in vivo anti-tumor efficacy of our compound was assessed by monitoring tumor growth in CT-26 syngeneic mouse model. Results: LCB33 ENPP1 inhibitor shows excellent ENPP1 inhibitory activity at an IC50 of 0.9pM and 1nM in enzyme assay using pNP-TMP and cGAMP as substrates, respectively. Our compound showed extensive ENPP1 selectivity in the PDE and kinase panel assays and favorable in vivo pharmacokinetic properties. The results from THP-1 dual reporter assay demonstrated the potency and efficacy of our compound which induce STING-mediated type I IFN release. In co-culture spheroids, our compounds induced immune cell penetration into spheroids, which indicates that immune-cell mediated tumor cell death via ENPP1 inhibition. Furthermore, LCB33 compound stimulated cytokine production without affecting to the proliferation of human T cells. Finally, in the CT-26 colorectal syngeneic mouse model, oral administration at 5 mg/kg demonstrated a TGI of 39% as monotherapy and a TGI of 72% in combination with anti-PD-L1, which describes our compound enhance anti-cancer effect of immune checkpoint blockade. Conclusions: Taken together, we report a novel and potent small molecule ENPP1 inhibitor in this study. Our ENPP1 inhibitor showed immune-cell mediated anti-cancer effects without affecting T cell proliferation. Additionally, we confirmed that our compounds showed synergistic anti-cancer effect with immune checkpoint blocker, anti-PD-L1, in colon-cancer mouse model. Further, we are going to perform Pharmacodynamic analysis in tumor infiltrating lymphocytes and tumor associated macrophages to verify immune-modulatory function of our ENPP1 inhibitors. Citation Format: Pyoung Oh Yoon, Juhyeon Kim, A-Ram Lee, Eunji Son, Young cheol Lee, Eunmi Jung, HyeongRae Kim, YeonHee Lee, SoEun Park, Dae-Yon Lee, Chul-Woong Chung. A novel small molecule inhibitor of ENPP1 promotes T and NK cell activation and enhances anti-tumor efficacy in combination with immune checkpoint blockade therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 702.

Structure-aided development of small molecule inhibitors of ENPP1, the extracellular phosphodiesterase of the immunotransmitter cGAMP

Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy

Development of Novel Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Tumor Immunotherapy

[1,2,4]Triazolo[1,5-a]pyrimidine derivatives: Structure-activity relationship study leading to highly selective ENPP1 inhibitors

Identification of novel pyrrolopyrimidine and pyrrolopyridine derivatives as potent ENPP1 inhibitors

Discovery of Pyrido[2,3- d ]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment

Discovery of orally bioavailable phosphonate prodrugs of potent ENPP1 inhibitors for cancer treatment

Abstract 702: A novel small molecule inhibitor of ENPP1 promotes T and NK cell activation and enhances anti-tumor efficacy in combination with immune checkpoint blockade therapy

Insight into small-molecule inhibitors targeting extracellular nucleotide pyrophosphatase/phosphodiesterase1 for potential multiple human diseases

Targeting ENPP1 for cancer immunotherapy: Killing two birds with one stone

Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 inhibitors: Research progress and prospects

Discovery of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one and 3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one derivatives as novel ENPP1 inhibitors

Structure-based virtual screening and in vitro validation of inhibitors of cyclic dinucleotide phosphodiesterases ENPP1 and CdnP

A novel small molecule Enpp1 inhibitor improves tumor control following radiation therapy by targeting stromal Enpp1 expression

ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer

ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway

A novel orally bioavailable small molecular ENPP1 inhibitor (OC-1) for cancer immunotherapy.

ENPP1 Immunobiology as a Therapeutic Target

Synthesis and structure-activity optimization of azepane-containing derivatives as PTPN2/PTPN1 inhibitors

Discovery of Imidazo[1,2- a ]pyrazine Derivatives as Potent ENPP1 Inhibitors

Discovery of VH domains that allosterically inhibit ENPP1